Targets of Acinetobacter baumannii

Inventors

Urwyler, Simon • Haake, Markus • Rudolf, Michael

Assignees

Aridis Pharmaceuticals Inc

Abstract

The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.

Core Innovation

The patent describes identification of Acinetobacter baumannii antigenic polypeptides and corresponding nucleic acids, including AB023, AB024, AB025, AB030, AB031 loop AB031L1, FimA, CsuAB, and OmpA, with corresponding SEQ ID NOs. The scope includes isolated polypeptides and recombinant nucleic acid molecules having specified nucleic acid sequences, as well as fragments, analogs, functional derivatives, and sequences having greater than 80% identity, stringently hybridizing sequences, and complementary sequences.

The patent further describes immunogenic compositions incorporating isolated polypeptides encoded by recombinant nucleic acid molecules, including an immuno-effective or effective amount of an adjuvant. The compositions are described as effective in generating or inducing an immune response against Acinetobacter baumannii in a subject in need thereof, and the adjuvant and optional delivery or vehicle components include multiple classes of vaccine and immunostimulatory agents.

The patent provides documented experimental and analytical evidence showing antigen reactivity and immune activity, including patient-convalescent sera antibody reactivity by ELISA and immunoblot, rabbit immunization reactivity, and antigen presence across clinical isolates by immunoblot. Functional immunology is supported by figures including FACS, agglutination, and bactericidal assays, along with mouse pneumonia immunization outcomes. Antigen-binding antibodies and antigen-binding fragments are described as targeting the identified antigens, including a preferred monoclonal binding consensus motif PVDFTVAI.

Claims Coverage

The independent claims cover immunogenic compositions formulated with specific isolated recombinant antigen components and an adjuvant to generate or induce an immune response against Acinetobacter baumannii. Across the independent claim set provided, the core inventive elements revolve around a particular recombinant nucleic acid polynucleotide sequence or a particular antigenic polypeptide amino acid sequence, in combination with an immuno-effective or effective amount of adjuvant.

Taken together, the independent claims provided define immunogenic compositions that use a specified recombinant antigen component, either a polypeptide encoded by a nucleic acid with SEQ ID NO: 3 or a recombinant antigenic polypeptide with amino acid sequence SEQ ID NO: 4, combined with an immuno-effective or effective adjuvant amount to generate or induce an immune response against Acinetobacter baumannii.

Stated Advantages

Documented Applications